Patents by Inventor Chenyu SHU

Chenyu SHU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Single-domain antibodies against CLL1 and constructs thereof
    Patent number: 12097219
    Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: September 24, 2024
    Assignee: Legend Biotech Ireland Limited
    Inventors: Wang Zhang, Yunlei Liu, Xiaojie Tu, Chenyu Shu, Tailan Zhan, Yun Zhang, An Tang, Yafeng Zhang, Shu Wu, Qing Zhang
  • CD30-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOF
    Publication number: 20220144960
    Abstract: CD30-binding moieties, chimeric antigen receptors (CARs) having these CD30-binding moieties, and uses thereof are provided. Polynucleotides encoding the CD30-binding moieties and CARs, compositions comprising CD30-binding moieties and CARs, genetically modified immune cells having a chimeric antigen receptor for use in adoptive cell therapy for treating CD30-expressing cancer or tumor in a subject in need thereof are also provided herein.
    Type: Application
    Filed: December 26, 2019
    Publication date: May 12, 2022
    Inventors: Shuai Yang, Sujuan Wang, Chenyu Shu, Yuanyuan Peng, Chen Hu, Shu Wu
  • SINGLE-DOMAIN ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
    Publication number: 20210277126
    Abstract: Provided are single-domain antibodies targeting CLL1 and constructs thereof, including chimeric receptors, immune effector cell engagers and immunoconjugates. Further provided are engineered immune effector cells (such as T cells) comprising an anti-CLL1 chimeric receptor and optionally a second chimeric receptor targeting a second antigen or epitope. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
    Type: Application
    Filed: September 10, 2019
    Publication date: September 9, 2021
    Inventors: Wang ZHANG, Yunlei LIU, Xiaojie TU, Chenyu SHU, Tailan ZHAN, Yun ZHANG, An TANG, Yafeng ZHANG, Shu WU, Qing ZHANG